improving care for one in five women evaluating and managing dyspareunia

  title={improving care for one in five women evaluating and managing dyspareunia},
  author={Donna Scemons and T M Egan},
Although one in five women will suffer from dyspareunia during her lifetime, only 15% of providers inquire about it. Unless the healthcare provider asks direct questions about this symptom most women will not discuss it. The following article examines several differential diagnoses and suggests interventions for dyspareunia, which can often be provided in the primary care setting. Etiologies of dyspareunia are both pathophysiological and psychosocial with both medications and nonpharmacological… 

Tables from this paper

Did I learn enough to practice? Reflections of new nurse practitioner graduates in providing sexual and reproductive health care
This study explores how nurse practitioners perceived their preparation and competency in providing a range of sexual and reproductive health care in their first two years of community-based practice.
improving care for one in five women evaluating and managing dyspareunia
Several differential diagnoses are examined and interventions for dyspareunia are suggested, which can often be provided in the primary care setting, according to women affected.


Dyspareunia in women.
Dyspareunia is recurrent or persistent pain with sexual activity that causes marked distress or interpersonal conflict. It affects approximately 10% to 20% of U.S. women. Dyspareunia can have a
Risk Factors for Dyspareunia After First Childbirth
Specific risk factors for dyspareunia in primiparous women that can be discussed at the first postpartum visit are identified, including breastfeeding, perineal pain, fatigue, and stress.
Biopsychosocial Factors Associated with Dyspareunia in a Community Sample of Adolescent Girls
Findings suggest that psychological variables, such as anxiety, play a significant role in painful intercourse’s very first manifestations in adolescent girls.
Vaginismus and subfertility: case reports on the association observed in clinical practice.
The case series aim to provide some insight on features and presentations of Asian women with vaginismus, characterised by persistent or recurrent difficulties in vaginal penetration despite the woman's wish for coitus.
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index, decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo.
Sex therapy for female sexual dysfunction
Sex therapy, as proposed by Masters and Johnson and Heiman and LoPiccolo, is still the most commonly used form of therapy for sexual Dysfunctions; although it has shown results, the results do not consistently support that this is the best alternative in the treatment of sexual dysfunctions.
Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
  • D. Edwards, N. Panay
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2016
A series of recommendations for the use of vaginal lubricants and moisturizers, either on their own or in combination with systemic or topical hormone replacement therapy, is presented.
Evaluation of Genito-Pelvic Pain/Penetration Disorder
With patients, “pain during intercourse” is the best wording to ease communication and GPPPD should include pain during anal intercourse and clitoral pain during penetration and/or at orgasm.
The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy
Treatment with ospemifene was consistently associated with greater improvement, substantial improvement or relief in the severity of the most bothersome symptoms of vaginal dryness or dyspareunia compared with placebo.